While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...

Donald Trump has launched a new war, this time against pharmaceutical companies. He has signed an executive order to reduce ...

As medications become increasingly popular to support weight loss, not all of them are approved by the U.S. Food and Drug ...

Viking Therapeutics became famous in the biotech world last year after announcing positive phase 2 results for VK2735, an investigational GLP-1 weight loss candidate. The stock has not performed well ...